TGTX TG Therapeutics: חובות לטווח קצר של החברה

Reviewing current loans and borrowings on GURU.Markets, it is evident that the value of 0.00 is a current indicator. TG Therapeutics, Inc. (TGTX) has pivoted to profitability following the launch of Briumvi after years of R&D expenditures. Revenues are based on insurance reimbursements for high-cost multiple sclerosis treatment. Michael Weiss's experienced management is successfully realizing the drug's commercial potential, confirming the team's qualifications.

This indicator captures total liabilities with maturities of up to one year, allowing for the identification of critical points where debt service costs begin to outpace operating cash flow. An analysis of short-term liability history confirms the financial stability of TG Therapeutics, Inc. (TGTX), whose expansion into multiple sclerosis therapy and the high efficacy of its primary drug minimize reliance on external borrowing.